OncoMatch/Clinical Trials/NCT07152678
Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell Carcinoma
Is NCT07152678 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Nivolumab (240 mg) for esophageal cancer.
Treatment: Nivolumab (240 mg) — The goal of this clinical trial is to learn if adding high-dose-rate (HDR) brachytherapy can improve outcomes in patients with locally advanced esophageal squamous cell carcinoma (ESCC) who have already received external beam radiotherapy (EBRT), chemotherapy, and the immune therapy drug nivolumab. The main questions it aims to answer are: * Does HDR brachytherapy reduce the chance of the cancer coming back in the esophagus or nearby areas within 12 months? * What side effects or safety issues occur when HDR brachytherapy is given after EBRT, chemotherapy, and nivolumab? Participants will: * Receive 1-2 sessions of HDR brachytherapy delivered through a thin tube placed inside the esophagus, within three weeks after starting nivolumab. * Continue nivolumab and be monitored with regular follow-up visits, imaging tests, and blood samples to check treatment response and safety.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) tumor cell (TC) ≥ 1% (TC ≥ 1%)
Biopsy proven with PD-L1 [tumor cell (TC) ≥ 1%]
Disease stage
Required: Stage III, IVA
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: external beam radiation therapy
Prior treatment with EBRT (40-50.4 Gy in 20-28 fractions)
Must have received: platinum-based chemotherapy
platinum + fluoropyrimidine chemotherapy
Must have received: fluoropyrimidine
platinum + fluoropyrimidine chemotherapy
Must have received: immune checkpoint inhibitor (nivolumab)
had received first cycle of nivolumab after CCRT
Cannot have received: immune checkpoint inhibitor
Exception: nivolumab after CCRT
No prior exposure to ICIs and had received first cycle of nivolumab after CCRT
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify